“Alpha-1 Antitrypsin Deficiency (AATD) Pipeline Insight, 2024” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Alpha-1 Antitrypsin Deficiency Market.
The Alpha-1 Antitrypsin Deficiency Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Alpha-1 Antitrypsin Deficiency (AATD) Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for the treatment of Alpha-1 Antitrypsin Deficiency and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Alpha-1 Antitrypsin Deficiency market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
Alpha1-Antitrypsin Deficiency (AATD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravitreal
-
Subretinal
-
Topical
Molecule Types
Products have been categorized under various Molecule types, such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Mechanism of Action of the Emerging Pipeline Therapies
-
Immunomodulators; Serine endopeptidase inhibitors
-
Alpha 1 antitrypsin modulators
-
Alpha 1 antitrypsin inhibitors; RNA interference
-
Leucocyte elastase inhibitors
-
Alpha 1 antitrypsin modulators; RNA interference
Learn How the Ongoing Clinical & Commercial Activities will Affect the Alpha-1 Antitrypsin Deficiency Therapeutic Segment @ https://www.delveinsight.com/sample-request/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight
Alpha-1 Antitrypsin Deficiency Therapeutics Landscape
There are approx. 12+ key companies developing therapies for Alpha1-Antitrypsin Deficiency (AATD). Currently, Arrowhead Pharmaceuticals is leading the therapeutics market with its Alpha1-Antitrypsin Deficiency (AATD) drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Alpha-1 Antitrypsin Deficiency Therapeutics Market Include:
-
Alnylam Pharmaceuticals
-
Arrowhead Pharmaceuticals
-
Beam Therapeutics
-
Centessa Pharmaceuticals
-
CSL Behring
-
Grifols
-
Inhibrx
-
Kamada
-
Kamada Ltd
-
LFB Biotechnologies
-
Mereo Biopharma
-
Promethera Biosciences
-
Santhera Pharmaceuticals
-
Shire
-
WaVe Life Sciences
And Many Others
Alpha1-Antitrypsin Deficiency (AATD) Drugs Covered in the Report Include
-
ALN-AAT02: Alnylam Pharmaceuticals
-
Alvelestat: Mereo Biopharma)
-
ARO AAT: Arrowhead Pharmaceuticals
-
DCR-A1AT: Dicerna Pharmaceuticals, Inc.
-
INBRX-101: Inhibrx, Inc.
-
Kamada-AAT for Inhalation: Kamada, Ltd.
-
VX-864: Vertex Pharmaceuticals Incorporated
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ https://www.delveinsight.com/sample-request/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight
Table of Contents
1. Report Introduction
2. Executive Summary
3. Alpha-1 Antitrypsin Deficiency Current Treatment Patterns
4. Alpha-1 Antitrypsin Deficiency – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Alpha-1 Antitrypsin Deficiency Late Stage Products (Phase-III)
7. Alpha-1 Antitrypsin Deficiency Mid-Stage Products (Phase-II)
8. Alpha-1 Antitrypsin Deficiency Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Alpha-1 Antitrypsin Deficiency Discontinued Products
13. Alpha-1 Antitrypsin Deficiency Product Profiles
14. Key Companies in the Alpha-1 Antitrypsin Deficiency Market
15. Key Products in the Alpha-1 Antitrypsin Deficiency Therapeutics Segment
16. Dormant and Discontinued Products
17. Alpha-1 Antitrypsin Deficiency Unmet Needs
18. Alpha-1 Antitrypsin Deficiency Future Perspectives
19. Alpha-1 Antitrypsin Deficiency Analyst Review
20. Appendix
21. Report Methodology
Download Sample PDF to Explore the Key Offerings of the Report @ https://www.delveinsight.com/sample-request/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/